U.S. Other Utilities Stock News

KE Holdings Inc. has already announced its Q4 and full-year 2025 results, reporting quarterly revenue of CNY 22,188.77 million and net income of CNY 87.85 million, alongside a new annual dividend of US$0.2260 per share payable on April 24, 2026. Along with a large-scale share repurchase program that has retired 41.14% of its shares since 2022 and inclusion in the Hang Seng China Enterprises Index, the company is emphasizing cost efficiency, AI-driven operations, and growing non-transaction...

In recent updates, Expand Energy outlined expectations for ongoing operational efficiencies in Fiscal 2026, including higher well productivity in the Haynesville formation and lower capital costs per foot across its natural gas and oil shale assets in Louisiana, Pennsylvania, West Virginia, and Ohio. This focus on productivity and cost discipline highlights how technology-driven improvements in core shale regions may increasingly shape the company’s operational profile and capital allocation...

FedEx (NYSE:FDX) is accelerating its Network 2.0 consolidation, including plans to close nine key shipping facilities. The company is moving toward a unified surface network that is intended to reshape its U.S. ground operations footprint. FedEx also plans a minority investment in InPost, a European out of home delivery specialist, signaling a push in parcel locker and pickup point services. For investors watching FedEx at a share price of $356.11, these moves highlight how the company is...

Large shareholder trims stake in Remitly Global (RELY) Naspers has sold 12 million Remitly Global (RELY) shares in the open market, cutting its indirect stake by about 47% and taking its holding below the SEC's 10% reporting threshold. The company has previously described Remitly as a non core asset. This sale fits within Naspers's broader divestiture program and puts fresh attention on Remitly's evolving ownership base and liquidity profile. See our latest analysis for Remitly...

In March 2026, Erasca, Inc. reported a full-year 2025 net loss of US$124.55 million, with basic loss per share from continuing operations of US$0.44, both improving versus the prior year. Earlier that month, Erasca exercised its option to expand its license with Joyo Pharmatech, securing exclusive global rights to the potential pan-RAS molecular glue ERAS-0015 and enabling a single worldwide development and commercialization plan. With Erasca now holding worldwide rights to ERAS-0015, we’ll...

In recent months, AST SpaceMobile has secured a US$30 million U.S. Space Development Agency contract, expanded commercial partnerships such as a Telus deal that includes an equity stake, advanced its BlueBird 6 and 7 satellite deployments, and reported its first year of revenue driven by multiple U.S. government contracts. These developments, alongside a US$1.20 billion contracted backlog, partnerships with more than 50 mobile network operators and increasing institutional ownership from...

CytomX Therapeutics recently reported full-year 2025 results showing sales of US$76.2 million and a net loss of US$17.37 million, and has just raised roughly US$250.00 million through a follow-on offering of common stock and pre-funded warrants at about US$5.30 per security. At the same time, the company released encouraging Phase 1 data for its EpCAM-targeted ADC Varseta-M in heavily pretreated metastatic colorectal cancer, with a high disease control rate and a safety profile that appears...

Elastic N.V. (NYSE:ESTC) is scheduled to participate in the HIMSS 2026 Global Health Conference & Exhibition. The event is one of the larger gatherings focused on healthcare IT and digital health solutions. Elastic's presence highlights its efforts to engage with healthcare providers, payers, and technology partners. For investors watching NYSE:ESTC, this appearance puts Elastic in front of a healthcare audience that depends heavily on search, observability, and data security tools...

Five Below (FIVE) has wrapped up FY 2026 with fourth quarter revenue of US$1.7b and basic EPS of US$4.32, supported by same store sales growth of 15.4%. Over the past few quarters, the company has seen revenue move from US$843.7m in Q3 2025 to US$1.0b in Q3 2026 and US$1.7b in Q4 2026, while quarterly basic EPS shifted from US$0.03 in Q3 2025 to US$0.66 in Q3 2026 and US$4.32 in the latest quarter, with trailing twelve month EPS at US$6.51. With trailing twelve month same store sales growth...

If you are wondering whether Ultragenyx Pharmaceutical's current share price reflects its true worth, the recent valuation checks offer some useful clues for your own research. The stock last closed at US$20.42, with returns of a 5.9% decline over 7 days, 1.2% over 30 days, a 13.5% decline year to date, and a 47.5% decline over the past year, which may change how you think about its risk and return profile. Ultragenyx has been in focus as investors reassess higher risk biotech names, and...

Titan America (NYSE:TTAM) has agreed to acquire Keystone Cement, expanding its presence and capacity in the Mid-Atlantic region. The company reports record revenue, EBITDA and operating cash flows for 2025, despite sector headwinds. These developments have not yet been widely discussed and may reshape Titan America's growth profile and operational footprint. For investors tracking NYSE:TTAM, the stock last closed at $14.71, with a 1 year return of 15.1% and a 12.0% decline year to date...

Callaway Golf stock in focus after name change Callaway Golf (CALY) is back in the spotlight after reverting to its historic name in January 2026, following a period as Topgolf Callaway Brands Corp. The move is drawing fresh attention to its core golf equipment and apparel business. See our latest analysis for Callaway Golf. The recent name change headlines arrive as momentum rebuilds, with a 16.9% year to date share price return and a 107.3% 1 year total shareholder return contrasting with...

Wondering if Colgate-Palmolive at around US$85.50 is offering fair value, or if you might be paying up for a quality brand name. The stock is up 10.1% year to date, even after a 2.8% slip over the last week and a 10.6% pullback over the past month. The 1-year return sits at a 3.0% decline and the 3- and 5-year returns are 27.8% and 23.6% respectively. These mixed returns often prompt investors to reassess what they are really paying for, especially when a consumer staple name like...

Why Protalix BioTherapeutics is Back on Investors’ Radar Protalix BioTherapeutics (PLX) has drawn fresh attention after the European Commission approved a new Elfabrio dosing regimen for certain Fabry disease patients, alongside updated 2026 revenue guidance that includes a US$25 million regulatory milestone. See our latest analysis for Protalix BioTherapeutics. The Elfabrio dosing news and 2026 guidance update arrive after a mixed share price pattern, with a 28.9% 90 day share price return...

Royal Caribbean Cruises (NYSE:RCL) has announced Royal Beach Club Lelepa, the first exclusive Royal Beach Club destination in the Southern Hemisphere. The company plans an expanded 2027 to 2028 cruise lineup across Australia, the South Pacific, New Zealand, and Asia. The program includes the return of key ships to Asia and Australia, with new itineraries aimed at attracting both new and repeat guests. Royal Caribbean Cruises, trading around $272.0, has seen a 3 year return of about 7x and a...

Recent commentary around Lam Research (LRCX) centers on its role in supplying equipment for AI focused data centers, with demand tied to DRAM, NAND, foundry spending, and process steps such as 3D DRAM and advanced packaging. See our latest analysis for Lam Research. At a share price of US$233.99, Lam Research has recently seen strong short term momentum, with a 4.13% 1 day share price return and 35.83% 90 day share price return. The 1 year total shareholder return of 203.94% and 5 year total...

Rare disease growth and Alimera deal draw fresh attention to ANI Pharmaceuticals ANI Pharmaceuticals (ANIP) is back on investor radar after strong growth in its rare disease business, led by Cortrophin Gel, and the completed acquisition of Alimera Sciences, which expanded the company’s ophthalmology product portfolio. See our latest analysis for ANI Pharmaceuticals. The recent attention around Cortrophin Gel and the Alimera deal comes as ANI’s share price, now at US$74.82, shows softer short...

American Express has removed Diversity, Equity, and Inclusion criteria from its board selection process following investor pressure. The change reflects growing debate in the U.S. over corporate DEI, ESG priorities, and shareholder rights. Both conservative and liberal investor groups have raised concerns about SEC actions that may affect proxy voting and disclosures. For investors watching NYSE:AXP, this governance shift comes as the share price stands at $294.93 and the stock has returned...

General Dynamics recently declared a regular quarterly dividend of US$1.59 per share, payable on May 8, 2026, to shareholders of record on April 10, 2026, following a past fourth-quarter report that showed revenue and earnings growth across all four segments and a very large increase in backlog. This combination of higher cash returns to shareholders and broad-based operational momentum highlights how General Dynamics is balancing near-term income with longer-term contract-driven...

Robinhood Markets (NasdaqGS:HOOD) has launched a limited-invite Social feature focused on community, strategy sharing, and social trading. The company has also brought Robinhood Ventures Fund I into public view, with disclosed positions in private companies such as Stripe and ElevenLabs. These updates follow earlier product news on credit cards, banking tools, and tokenized assets, and point to a broader expansion of Robinhood's business model. For readers watching NasdaqGS:HOOD, these...

Wondering whether Xcel Energy's current share price reflects its true worth, or if the recent performance is masking a better or worse deal than it looks on the surface? The stock last closed at US$79.53, with returns of 6.5% year to date and 18.7% over the past year. This puts recent price moves firmly on investors' radar. Recent coverage has focused on Xcel Energy's role as a regulated utility and ongoing grid and infrastructure spending. This helps frame how investors view its long term...

Buyback announcement sets the stage Kimbell Royalty Partners (KRP) has authorized a share repurchase program of up to US$100 million, funded by cash on hand, free cash flow, or its revolving credit facility through December 31, 2027. See our latest analysis for Kimbell Royalty Partners. At a share price of US$14.51, Kimbell Royalty Partners has posted a 27.73% 90 day share price return and a 154.70% five year total shareholder return, with the recent buyback announcement and stronger Q4 2025...

American Eagle Outfitters (AEO) has just been upgraded to a top analyst ranking, with earnings projections and sentiment turning more positive. This places its earnings outlook and recent stock performance under closer investor scrutiny. See our latest analysis for American Eagle Outfitters. The recent upgrade and brighter earnings outlook come after a sharp shift in momentum, with a 1-day share price return of 1.45% contrasting with a 30-day share price return of 29.8% and a 90-day share...

The UK Competition and Markets Authority has opened a probe into Adobe's subscription cancellation terms and fees. Regulators are examining whether early exit charges and related disclosures for Adobe plans are unfair, misleading, or unclear for UK customers. The investigation focuses on Adobe's subscription contracts for creative and digital tools, and how users are informed about costs when cancelling. Adobe, listed as NasdaqGS:ADBE, runs a subscription heavy model across its Creative...